Skip to main content

Clinical Data to Develop Dx to Predict Response Rate for Rituximab

NEW YORK (GenomeWeb News) — Clinical Data plans to develop a molecular diagnostic aimed at identifying patients likely to respond to a monoclonal antibody made by Genentech/Biogen-Idec and Roche
 
The deal calls for Clinical Data to measure patient response to rituximab, which is used to treat non-Hodgkins lymphoma and rheumatoid arthritis. The company reported yesterday that it has signed a licensing agreement for “an extensive portfolio of patents” toward this goal, but would not disclose the name of the licenser.
 
Clinical Data said the diagnostic will employ a variation in the FCGRIIIA gene, which will have a greater than 90-percent specificity in predicting response to rituximab in NHL.
 
The company also expects that this gene will be useful in measuring response to other monoclonal antibodies used to treat Crohn’s disease and other inflammatory disorders.
 

Genentech recently licensed a gene map of Crohn’s disease from Genizon Biosciences.

 

 

CD said it expects to begin working on the rituximab diagnostic in early 2007.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.